Diabetes & Metabolism Journal

Original Articles

Obesity and Metabolic Syndrome
The Association between Z-Score of Log-Transformed A Body Shape Index and Cardiovascular Disease in Korea: Wankyo Chung, Jung Hwan Park, Hye Soo Chung, Jae Myung Yu, Shinje Moon, Dong Sun Kim; Diabetes Metab J. 2019;43(5):675-682. Published online April 26, 2019; DOI: https://doi.org/10.4093/dmj.2018.0169

8,457 View
60 Download
3 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader

Background

In order to overcome the limitations of body mass index (BMI) and waist circumference (WC), the z-score of the log-transformed A Body Shape Index (LBSIZ) has recently been introduced. In this study, we analyzed the relationship between the LBSIZ and cardiovascular disease (CVD) in a Korean representative sample.

Methods

Data were collected from the Korea National Health and Nutrition Examination VI to V. The association between CVD and obesity indices was analyzed using a receiver operating characteristic curve. The cut-off value for the LBSIZ was estimated using the Youden index, and the odds ratio (OR) for CVD was determined via multivariate logistic regression analysis. ORs according to the LBSIZ value were analyzed using restricted cubic spline regression plots.

Results

A total of 31,227 Korean healthy adults were analyzed. Area under the curve (AUC) of LBSIZ against CVD was 0.686 (95% confidence interval [CI], 0.671 to 0.702), which was significantly higher than the AUC of BMI (0.583; 95% CI, 0.567 to 0.599) or WC (0.646; 95% CI, 0.631 to 0.661) (P<0.001). Similar results were observed for stroke and coronary artery diseases. The cut-off value for the LBSIZ was 0.35 (sensitivity, 64.5%; specificity, 64%; OR, 1.29, 95% CI, 1.12 to 1.49). Under restricted cubic spline regression, LBSIZ demonstrated that OR started to increase past the median value.

Conclusion

The findings of this study suggest that the LBSIZ might be more strongly associated with CVD risks compared to BMI or WC. These outcomes would be helpful for CVD risk assessment in clinical settings, especially the cut-off value of the LBSIZ suggested in this study.

Citations

Citations to this article as recorded by

Body Shape Index and Cardiovascular Risk in Individuals With Obesity
Nazlı Hacıağaoğlu, Can Öner, Hüseyin Çetin, Engin Ersin Şimşek
Cureus.2022;[Epub] CrossRef
Association between body shape index and risk of mortality in the United States
Heysoo Lee, Hye Soo Chung, Yoon Jung Kim, Min Kyu Choi, Yong Kyun Roh, Wankyo Chung, Jae Myung Yu, Chang-Myung Oh, Shinje Moon
Scientific Reports.2022;[Epub] CrossRef
Utility of the Z-score of log-transformed A Body Shape Index (LBSIZ) in the assessment for sarcopenic obesity and cardiovascular disease risk in the United States
Wankyo Chung, Jung Hwan Park, Hye Soo Chung, Jae Myung Yu, Dong Sun Kim, Shinje Moon
Scientific Reports.2019;[Epub] CrossRef

Clinical Diabetes & Therapeutics
Association between Serum Selenium Level and the Presence of Diabetes Mellitus: A Meta-Analysis of Observational Studies: Juno Kim, Hye Soo Chung, Min-Kyu Choi, Yong Kyun Roh, Hyung Joon Yoo, Jung Hwan Park, Dong Sun Kim, Jae Myung Yu, Shinje Moon; Diabetes Metab J. 2019;43(4):447-460. Published online January 2, 2019; DOI: https://doi.org/10.4093/dmj.2018.0123

7,009 View
104 Download
35 Web of Science
36 Crossref

Abstract PDF Supplementary Material PubReader

Background

Epidemiological studies have suggested an association between selenium (Se) and diabetes mellitus (DM). However, different studies have reported conflicting results. Therefore, we performed a comprehensive meta-analysis to clarify the impact of Se on DM.

Methods

We searched the PubMed database for studies on the association between Se and DM from inception to June 2018.

Results

Twenty articles evaluating 47,930 participants were included in the analysis. The meta-analysis found that high levels of Se were significantly associated with the presence of DM (pooled odds ratios [ORs], 1.88; 95% confidence interval [CI], 1.44 to 2.45). However, significant heterogeneity was found (I²=82%). Subgroup analyses were performed based on the Se measurement methods used in each study. A significant association was found between high Se levels and the presence of DM in the studies that used blood (OR, 2.17; 95% CI, 1.60 to 2.93; I²=77%), diet (OR, 1.61; 95% CI, 1.10 to 2.36; I²=0%), and urine (OR, 1.49; 95% CI, 1.02 to 2.17; I²=0%) as samples to estimate Se levels, but not in studies on nails (OR, 1.24; 95% CI, 0.52 to 2.98; I²=91%). Because of significant heterogeneity in the studies with blood, we conducted a sensitivity analysis and tested the publication bias. The results were consistent after adjustment based on the sensitivity analysis as well as the trim and fill analysis for publication bias.

Conclusion

This meta-analysis demonstrates that high levels of Se are associated with the presence of DM. Further prospective and randomized controlled trials are warranted to elucidate the link better.

Citations

Citations to this article as recorded by

Selenium Species in Diabetes Mellitus Type 2
Krystyna Pyrzynska, Aleksandra Sentkowska
Biological Trace Element Research.2024; 202(7): 2993. CrossRef
Increased Expression of PHGDH Under High-Selenium Stress In Vivo
Qin Wang, Jianrong Wang, Xue Zhang, Yiqun Liu, Feng Han, Xuesong Xiang, Yanbin Guo, Zhen-wu Huang
Biological Trace Element Research.2024; 202(11): 5145. CrossRef
Dosage-effect of selenium supplementation on blood glucose and oxidative stress in type 2 diabetes mellitus and normal mice
Xiaxia Cai, Zhuo Hu, Mingyuan Zhang, Qinyu Dang, Qian Yang, Xiaoyan Zhao, Yandi Zhu, Yadi Zhang, Yuchen Wei, Haiqin Fang, Huanling Yu
Journal of Trace Elements in Medicine and Biology.2024; 83: 127410. CrossRef
Immunomodulation through Nutrition Should Be a Key Trend in Type 2 Diabetes Treatment
Katarzyna Napiórkowska-Baran, Paweł Treichel, Marta Czarnowska, Magdalena Drozd, Kinga Koperska, Agata Węglarz, Oskar Schmidt, Samira Darwish, Bartłomiej Szymczak, Zbigniew Bartuzi
International Journal of Molecular Sciences.2024; 25(7): 3769. CrossRef
The Immunomodulatory Effects of Selenium: A Journey from the Environment to the Human Immune System
Rebecka A. Sadler, Bonnie A. Mallard, Umesh K. Shandilya, Mohammed A. Hachemi, Niel A. Karrow
Nutrients.2024; 16(19): 3324. CrossRef
Biological Activity of Selenium and Its Impact on Human Health
Giuseppe Genchi, Graziantonio Lauria, Alessia Catalano, Maria Stefania Sinicropi, Alessia Carocci
International Journal of Molecular Sciences.2023; 24(3): 2633. CrossRef
The Role of Selenium and Manganese in the Formation, Diagnosis and Treatment of Cervical, Endometrial and Ovarian Cancer
Anna Golara, Mateusz Kozłowski, Paweł Guzik, Sebastian Kwiatkowski, Aneta Cymbaluk-Płoska
International Journal of Molecular Sciences.2023; 24(13): 10887. CrossRef
Association of Selenium Intake and Selenium Concentrations with Risk of Type 2 Diabetes in Adults: A Narrative Review
Maha Alharithy, Nora Alafif
Metabolites.2023; 13(6): 767. CrossRef
Selenium-Containing Organic Fertilizer Application Affects Yield, Quality, and Distribution of Selenium in Wheat
Peng Chen, Hiba Shaghaleh, Yousef Alhaj Hamoud, Jing Wang, Wenxia Pei, Xianfu Yuan, Jianjian Liu, Cece Qiao, Wenhui Xia, Jianfei Wang
Life.2023; 13(9): 1849. CrossRef
A Comprehensive Review on Selenium and Its Effects on Human Health and Distribution in Middle Eastern Countries
Marek Kieliszek, Iqra Bano, Hamed Zare
Biological Trace Element Research.2022; 200(3): 971. CrossRef
Selenium and clarithromycin loaded PLA-GO composite wound dressings by electrospinning method
Fatih Ciftci, Sumeyra Ayan, Nilüfer Duygulu, Yasemin Yilmazer, Zeynep Karavelioglu, Meyrem Vehapi, Rabia Cakır Koc, Mustafa Sengor, Hakan Yılmazer, Didem Ozcimen, Oguzhan Gunduz, Cem Bulent Ustundag
International Journal of Polymeric Materials and Polymeric Biomaterials.2022; 71(12): 898. CrossRef
The role of selenium in type-2 diabetes mellitus and its metabolic comorbidities
Holger Steinbrenner, Leonidas H. Duntas, Margaret P. Rayman
Redox Biology.2022; 50: 102236. CrossRef
The Role of Selenium in Pathologies: An Updated Review
Giulia Barchielli, Antonella Capperucci, Damiano Tanini
Antioxidants.2022; 11(2): 251. CrossRef
Selenium and Selenoproteins at the Intersection of Type 2 Diabetes and Thyroid Pathophysiology
Francesca Gorini, Cristina Vassalle
Antioxidants.2022; 11(6): 1188. CrossRef
Higher selenium was associated with higher risk of diabetes: Consistent evidence from longitudinal and cross-sectional studies based on nail and serum selenium measures
Ranqi Shao, Liqin Su, Li Li, Jinghuan Wu, Xiaohong He, Deqian Mao, Yibin Cheng, Jingyi Liu, Chen Chen, Yinlong Jin, Sujuan Gao
Science of The Total Environment.2022; 840: 156618. CrossRef
The Roles and Pathogenesis Mechanisms of a Number of Micronutrients in the Prevention and/or Treatment of Chronic Hepatitis, COVID-19 and Type-2 Diabetes Mellitus
Khalid M. Sumaily
Nutrients.2022; 14(13): 2632. CrossRef
Associations between Circulating SELENOP Level and Disorders of Glucose and Lipid Metabolism: A Meta-Analysis
Ruirui Yu, Zhoutian Wang, Miaomiao Ma, Ping Xu, Longjian Liu, Alexey A. Tinkov, Xin Gen Lei, Ji-Chang Zhou
Antioxidants.2022; 11(7): 1263. CrossRef
Cross-Sectional Association of Blood Selenium with Glycemic Biomarkers among U.S. Adults with Normoglycemia in the National Health and Nutrition Examination Survey 2013–2016
Jingli Yang, En Chen, Cheukling Choi, Kayue Chan, Qinghua Yang, Juwel Rana, Bo Yang, Chuiguo Huang, Aimin Yang, Kenneth Lo
Nutrients.2022; 14(19): 3972. CrossRef
Plasma and vitreous selenium concentrations in patients with type 2 diabetes and diabetic retinopathy
Chunmiao Wang, Ruijin Ran, Xin Jin, Xiaohong Zhu
Medicine.2022; 101(39): e30877. CrossRef
Emerging roles of selenium on metabolism and type 2 diabetes
Jiuxiang Zhao, Hong Zou, Yanling Huo, Xiaoyi Wei, Yu Li
Frontiers in Nutrition.2022;[Epub] CrossRef
Selenium: Role in preserving and improving health and preventing disease
Goran Belojević
Galenika Medical Journal.2022; 1(4): 90. CrossRef
A comprehensive review on the neuropathophysiology of selenium
Mohammad Naderi, Pankaj Puar, Mahtab Zonouzi-Marand, Douglas P. Chivers, Som Niyogi, Raymond W.M. Kwong
Science of The Total Environment.2021; 767: 144329. CrossRef
Dietary selenium intake and risk of hospitalization for type 2 diabetes in the Moli-sani study cohort
Marco Vinceti, Marialaura Bonaccio, Tommaso Filippini, Simona Costanzo, Lauren A. Wise, Augusto Di Castelnuovo, Emilia Ruggiero, Mariarosaria Persichillo, Chiara Cerletti, Maria Benedetta Donati, Giovanni de Gaetano, Licia Iacoviello
Nutrition, Metabolism and Cardiovascular Diseases.2021; 31(6): 1738. CrossRef
A systematic review and dose-response meta-analysis of exposure to environmental selenium and the risk of type 2 diabetes in nonexperimental studies
Marco Vinceti, Tommaso Filippini, Lauren A. Wise, Kenneth J. Rothman
Environmental Research.2021; 197: 111210. CrossRef
Selenium as a Bioactive Micronutrient in the Human Diet and Its Cancer Chemopreventive Activity
Dominika Radomska, Robert Czarnomysy, Dominik Radomski, Anna Bielawska, Krzysztof Bielawski
Nutrients.2021; 13(5): 1649. CrossRef
Selenium in Human Health and Gut Microflora: Bioavailability of Selenocompounds and Relationship With Diseases
Rannapaula Lawrynhuk Urbano Ferreira, Karine Cavalcanti Maurício Sena-Evangelista, Eduardo Pereira de Azevedo, Francisco Irochima Pinheiro, Ricardo Ney Cobucci, Lucia Fatima Campos Pedrosa
Frontiers in Nutrition.2021;[Epub] CrossRef
Ferroptosis and Its Potential Role in Metabolic Diseases: A Curse or Revitalization?
Jia-Yue Duan, Xiao Lin, Feng Xu, Su-Kang Shan, Bei Guo, Fu-Xing-Zi Li, Yi Wang, Ming-Hui Zheng, Qiu-Shuang Xu, Li-Min Lei, Wen-Lu Ou-Yang, Yun-Yun Wu, Ke-Xin Tang, Ling-Qing Yuan
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Selenium Intake and Glycemic Control in Young Adults With Normal-Weight Obesity Syndrome
Acsa de Castro Santos, Anna Flavia Ferreira Passos, Luciana Carla Holzbach, Cristiane Cominetti
Frontiers in Nutrition.2021;[Epub] CrossRef
Development and Therapeutic Potential of Selenazo Compounds
Ana Carolina Ruberte, Carmen Sanmartin, Carlos Aydillo, Arun K. Sharma, Daniel Plano
Journal of Medicinal Chemistry.2020; 63(4): 1473. CrossRef
Selenium in thyroid disorders — essential knowledge for clinicians
Kristian Hillert Winther, Margaret Philomena Rayman, Steen Joop Bonnema, Laszlo Hegedüs
Nature Reviews Endocrinology.2020; 16(3): 165. CrossRef
Safety of selenium‐enriched biomass of Yarrowia lipolytica as a novel food pursuant to Regulation (EU) 2015/2283
Dominique Turck, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch‐Ernst, John Kearney, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Marc
EFSA Journal.2020;[Epub] CrossRef
The Association of Circulating Selenium Concentrations with Diabetes Mellitus

Xiao-Long Liao, Zhong-Hua Wang, Xiu-Na Liang, Jun Liang, Xue-Biao Wei, Shou-Hong Wang, Wei-Xin Guo
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 4755. CrossRef
A 2018 European Thyroid Association Survey on the Use of Selenium Supplementation in Hashimoto’s Thyroiditis
Kristian Hillert Winther, Enrico Papini, Roberto Attanasio, Roberto Negro, Laszlo Hegedüs
European Thyroid Journal.2020; 9(2): 99. CrossRef
Systems Biology of Selenium and Complex Disease
Huimin Ying, Yan Zhang
Biological Trace Element Research.2019; 192(1): 38. CrossRef
Effectiveness and safety of selenium supplementation for type 2 diabetes mellitus in adults: a systematic review of randomised controlled trials
A. Stróżyk, Z. Osica, J. D. Przybylak, M. Kołodziej, B. M. Zalewski, B. Mrozikiewicz‐Rakowska, H. Szajewska
Journal of Human Nutrition and Dietetics.2019; 32(5): 635. CrossRef
Selenium and Health: An Update on the Situation in the Middle East and North Africa
Sohayla A. Z. Ibrahim, Abdelhamid Kerkadi, Abdelali Agouni
Nutrients.2019; 11(7): 1457. CrossRef

Obesity and Metabolic Syndrome
Proportion and Characteristics of the Subjects with Low Muscle Mass and Abdominal Obesity among the Newly Diagnosed and Drug-Naïve Type 2 Diabetes Mellitus Patients: Jung A Kim, Soon Young Hwang, Hye Soo Chung, Nam Hoon Kim, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo; Diabetes Metab J. 2019;43(1):105-113. Published online September 28, 2018; DOI: https://doi.org/10.4093/dmj.2018.0036

5,583 View
79 Download
14 Web of Science
16 Crossref

Abstract PDF PubReader

Background

Sarcopenic obesity (SO) is a serious public health concern, few studies have examined the clinical implications of SO in newly-diagnosed type 2 diabetes mellitus (T2DM) patients. We evaluated the prevalence of the newly diagnosed, drug-naïve T2DM patients with low muscle mass with abdominal obesity and its association with insulin resistance and other diabetic complications.

Methods

We classified 233 drug-naïve T2DM subjects into four groups according to abdominal obesity (waist circumference ≥90 cm in men and ≥85 cm in women) and low muscle mass status (appendicular skeletal muscle <7.0 kg/m² for men and <5.4 kg/m² for women).

Results

The proportion of the subjects with low muscle mass and abdominal obesity among the newly diagnosed, drug-naïve T2DM patients was 8.2%. Homeostasis model assessment of insulin resistance (HOMA-IR) increased linearly according to body composition group from normal to abdominal obesity to both low muscle mass and abdominal obesity. The multiple logistic regression analysis indicated that subjects with low muscle mass and abdominal obesity (odds ratio [OR], 9.39; 95% confidence interval [CI], 2.41 to 36.56) showed a higher risk for insulin resistance, defined as HOMA-IR ≥3, than those with abdominal obesity (OR, 5.36; 95% CI, 2.46 to 11.69), even after adjusting for other covariates. However, there were no differences in lipid profiles, microalbuminuria, or various surrogate markers for atherosclerosis among the four groups.

Conclusion

Subjects with both low muscle mass and abdominal obesity had a higher risk of insulin resistance than those with low muscle mass or abdominal obesity only.

Citations

Citations to this article as recorded by

Coexistence of high visceral fat area and sarcopenia is associated with atherosclerotic markers in old‐old patients with diabetes: A cross‐sectional study
Motoya Sato, Yoshiaki Tamura, Yuji Murao, Fumino Yorikawa, Yuu Katsumata, So Watanabe, Shugo Zen, Remi Kodera, Kazuhito Oba, Kenji Toyoshima, Yuko Chiba, Atsushi Araki
Journal of Diabetes Investigation.2024; 15(10): 1510. CrossRef
The coexistence of low muscle mass and obesity evaluated by dual energy X‐ray absorptiometry, rather than low muscle mass or obesity alone, is associated with macrovascular but not microvascular complications in patients with type 2 diabetes mellitus
Han Li, Weijuan Su, Zeyu Zheng, Jia Li, Shunhua Wang, Zheng Chen, Yuxian Zhang, Bingkun Huang, Fuping Lyu, Fangfang Yan, Caoxin Huang, Mingzhu Lin, Xiulin Shi, Xuejun Li
Diabetes, Obesity and Metabolism.2024;[Epub] CrossRef
Clinical observation on acupuncture for 80 patients with abdominal obesity in Germany: based on the theory of unblocking and regulating the Belt Vessel
Yuanyuan Li, Hang Xiong, Shuhui Ma, Jingzhang Dai
Journal of Acupuncture and Tuina Science.2023; 21(2): 137. CrossRef
Waist circumference and end‐stage renal disease based on glycaemic status: National Health Insurance Service data 2009–2018
Yun Kyung Cho, Ji Hye Huh, Shinje Moon, Yoon Jung Kim, Yang‐Hyun Kim, Kyung‐do Han, Jun Goo Kang, Seong Jin Lee, Sung‐Hee Ihm
Journal of Cachexia, Sarcopenia and Muscle.2023; 14(1): 585. CrossRef
Incidence of sarcopenic obesity in older patients with diabetes and association between sarcopenic obesity and higher-level functional capacity: evaluation based on a consensus statement
Satoshi Ida, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Kentaro Azuma, Kazuya Murata
Endocrine Journal.2023; 70(6): 591. CrossRef
A Novel Anthropometric Parameter, Weight-Adjusted Waist Index Represents Sarcopenic Obesity in Newly Diagnosed Type 2 Diabetes Mellitus
Min Jeong Park, Soon Young Hwang, Nam Hoon Kim, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
Journal of Obesity & Metabolic Syndrome.2023; 32(2): 130. CrossRef
Prevalence of sarcopenic obesity in patients with diabetes and adverse outcomes: A systematic review and meta-analysis
Yuan-yuan Zhou, Jin-feng Wang, Qian Yao, Qiu-feng Jian, Zhi-peng Luo
Clinical Nutrition ESPEN.2023; 58: 128. CrossRef
The Correlation Between Leg Muscle Mass Index and Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
Menggege Liu, Qing Zhang, Juan Liu, Huiling Bai, Ping Yang, Xinhua Ye, Xiaoqing Yuan
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 4169. CrossRef
Sarcopenic Obesity with Normal Body Size May Have Higher Insulin Resistance in Elderly Patients with Type 2 Diabetes Mellitus
Tingting Han, Ting Yuan, Xinyue Liang, Ningxin Chen, Jia Song, Xin Zhao, Yurong Weng, Yaomin Hu
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1197. CrossRef
Relationship between Visceral Adipose Index, Lipid Accumulation Product and Type 2 Diabetes Mellitus
停停陈
Advances in Clinical Medicine.2022; 12(04): 3350. CrossRef
Assessment of the relationship between prediabetes and low skeletal mass based on blood creatinine level
S. I. Ibragimova, G. O. Nuskabayeva, Z. N. Shalkharova, K. Zh. Sadykova, G. A. Junusbekova, M. Oran
Diabetes mellitus.2022; 25(3): 226. CrossRef
Changes in body composition and low blood urea nitrogen level related to an increase in the prevalence of fatty liver over 20 years: A cross‐sectional study
Yasushi Imamura, Seiichi Mawatari, Kohei Oda, Kotaro Kumagai, Yasunari Hiramine, Akiko Saishoji, Atsuko Kakihara, Mai Nakahara, Manei Oku, Kaori Hosoyamada, Shuji Kanmura, Akihiro Moriuchi, Hironori Miyahara, Akio ido
Hepatology Research.2021; 51(5): 570. CrossRef
Body Composition and Diabetes
Hye Jin Yoo
The Journal of Korean Diabetes.2021; 22(4): 238. CrossRef
Reduced Skeletal Muscle Volume and Increased Skeletal Muscle Fat Deposition Characterize Diabetes in Individuals after Pancreatitis: A Magnetic Resonance Imaging Study
Andre E. Modesto, Juyeon Ko, Charlotte E. Stuart, Sakina H. Bharmal, Jaelim Cho, Maxim S. Petrov
Diseases.2020; 8(3): 25. CrossRef
Low alanine aminotransferase levels predict low muscle strength in older patients with diabetes: A nationwide cross‐sectional study in Korea
Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
Geriatrics & Gerontology International.2020; 20(4): 271. CrossRef
Association between sarcopenic obesity and higher risk of type 2 diabetes in adults: A systematic review and meta-analysis
Dima Khadra, Leila Itani, Hana Tannir, Dima Kreidieh, Dana El Masri, Marwan El Ghoch
World Journal of Diabetes.2019; 10(5): 311. CrossRef

Smaller Mean LDL Particle Size and Higher Proportion of Small Dense LDL in Korean Type 2 Diabetic Patients: Sunghwan Suh, Hyung-Doo Park, Se Won Kim, Ji Cheol Bae, Alice Hyun-Kyung Tan, Hye Soo Chung, Kyu Yeon Hur, Jae Hyeon Kim, Kwang-Won Kim, Moon-Kyu Lee; Diabetes Metab J. 2011;35(5):536-542. Published online October 31, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.5.536

5,491 View
49 Download
15 Crossref

Abstract PDF PubReader

Background

Small dense low density lipoprotein (sdLDL) has recently emerged as an important risk factor of coronary heart disease.

Methods

The mean LDL particle size was measured in 203 patients with type 2 diabetes mellitus (T2DM) and 212 matched subjects without diabetes using polyacrylamide tube gel electrophoresis. Major vascular complications were defined as stroke, angiographically-documented coronary artery disease or a myocardial infarction. Peripheral vascular stenosis, carotid artery stenosis (≥50% in diameter) or carotid artery plaque were considered minor vascular complications. Overall vascular complications included both major and minor vascular complications.

Results

Diabetic patients had significantly smaller mean-LDL particle size (26.32 nm vs. 26.49 nm) and a higher percentage of sdLDL to total LDL compared to those of subjects without diabetes (21.39% vs. 6.34%). The independent predictors of sdLDL in this study were serum triglyceride level and body mass index (odds ratio [OR], 1.020 with P<0.001 and OR 1.152 with P<0.027, respectively). However, no significant correlations were found between sdLDL and major vascular complications (P=0.342), minor vascular complications (P=0.573) or overall vascular complications (P=0.262) in diabetic subjects.

Conclusion

Diabetic patients had a smaller mean-LDL particle size and higher proportion of sdLDL compared to those of subjects without diabetes. Obese diabetic patients with hypertriglyceridemia have an increased risk for atherogenic small dense LDL. However, we could not verify an association between LDL particle size and vascular complications in this study.

Citations

Citations to this article as recorded by

Evaluation of measured and calculated small dense low-density lipoprotein in capillary blood and association with the metabolic syndrome
Sara Deza, Inmaculada Colina, Oscar Beloqui, José Ignacio Monreal, Estéfani Martínez-Chávez, Julia Maroto-García, Carmen Mugueta, Alvaro González, Nerea Varo
Clinica Chimica Acta.2024; 557: 117897. CrossRef
Nrf2 Signaling Pathway as a Key to Treatment for Diabetic Dyslipidemia and Atherosclerosis
Michelle Yi, Arvin John Toribio, Yusuf Muhammad Salem, Michael Alexander, Antoney Ferrey, Lourdes Swentek, Ekamol Tantisattamo, Hirohito Ichii
International Journal of Molecular Sciences.2024; 25(11): 5831. CrossRef
Association between measured or calculated small dense low‐density lipoprotein cholesterol and oxidized low‐density lipoprotein in subjects with or without type 2 diabetes mellitus
Hyun‐Ki Kim, Jinyoung Hong, Sunyoung Ahn, Woochang Lee, Sail Chun, Won‐Ki Min
Journal of Clinical Laboratory Analysis.2023;[Epub] CrossRef
The association of apolipoprotein in the risk of ST-elevation myocardial infarction in patients with documented coronary artery disease
Astuti Giantini, Nur Gifarani Pratiwi, Renan Sukmawan, Joedo Prihartono, Suzanna Immanuel, Merci Monica Pasaribu, Sri Suryo Adiyanti, Yusuf Bahasoan
International Journal of Cardiology Cardiovascular Risk and Prevention.2023; 18: 200194. CrossRef
Atherogenic Index of Plasma and Its Association with Risk Factors of Coronary Artery Disease and Nutrient Intake in Korean Adult Men: The 2013–2014 KNHANES
Hye Ran Shin, SuJin Song, Jin Ah Cho, Sun Yung Ly
Nutrients.2022; 14(5): 1071. CrossRef
The Atherogenic Index of Plasma: A Powerful and Reliable Predictor for Coronary Artery Disease in Patients With Type 2 Diabetes
Kuo Zhou, Zheng Qin, Jinfan Tian, Kongyong Cui, Yunfeng Yan, Shuzheng Lyu
Angiology.2021; 72(10): 934. CrossRef
Direct bilirubin is associated with low-density lipoprotein subfractions and particle size in overweight and centrally obese women
Y.-J. Kwon, H.-S. Lee, J.-W. Lee
Nutrition, Metabolism and Cardiovascular Diseases.2018; 28(10): 1021. CrossRef
Correlation between Cholesterol, Triglycerides, Calculated, and Measured Lipoproteins: Whether Calculated Small Density Lipoprotein Fraction Predicts Cardiovascular Risks
Sikandar Hayat Khan, Nadeem Fazal, Athar Abbas Gilani Shah, Syed Mohsin Manzoor, Naveed Asif, Aamir Ijaz, Najmusaqib Khan Niazi, Muhammad Yasir
Journal of Lipids.2017; 2017: 1. CrossRef
Effects of Small Dense LDL in Diabetic Nephropathy in Females with Type 2 Diabetes Mellitus
Seongyul Ryu, Youngwoo Kim, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Hyun Baek, Ki-Ho Song, Kyung-Jin Yun
Journal of Lipid and Atherosclerosis.2016; 5(1): 11. CrossRef
Prepregnancy Adverse Lipid Profile and Subsequent Risk of Gestational Diabetes
Emily S. Han, Ronald M. Krauss, Fei Xu, Sneha B. Sridhar, Assiamira Ferrara, Charles P. Quesenberry, Monique M. Hedderson
The Journal of Clinical Endocrinology & Metabolism.2016; 101(7): 2721. CrossRef
Meta-analysis of Atherogenic Index of Plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus
Xiao-Wei Zhu, Fei-Yan Deng, Shu-Feng Lei
Primary Care Diabetes.2015; 9(1): 60. CrossRef
Higher levels of small dense low‐density lipoprotein (LDL) are associated with cardiac autonomic neuropathy in patients with Type 2 diabetes
E.‐H. Jang, Y.‐M. Park, J. Hur, M.‐K. Kim, S.‐H. Ko, K.‐H. Baek, K.‐H. Song, K.‐W. Lee, H.‐S. Kwon
Diabetic Medicine.2013; 30(6): 694. CrossRef
Sleep Status and Low-Density Lipoprotein Particle Size in a General Japanese Female Population: The Mima Study
Kazuhiko Kotani, Kokoro Tsuzaki, Shinji Fujiwara, Naoki Sakane
Medical Principles and Practice.2013; 22(5): 510. CrossRef
Serum small-dense LDL abnormalities in chronic renal disease patients
M. Chu, A. Y. M. Wang, I. H. S. Chan, S. H. Chui, C. W. K. Lam
British Journal of Biomedical Science.2012; 69(3): 99. CrossRef
Small Dense Low-density Lipoprotein and Cardiovascular Disease
Sunghwan Suh, Moon-Kyu Lee
Journal of Lipid and Atherosclerosis.2012; 1(1): 1. CrossRef

Efficacy of Sitagliptin When Added to Ongoing Therapy in Korean Subjects with Type 2 Diabetes Mellitus: Hye Soo Chung, Moon-Kyu Lee; Diabetes Metab J. 2011;35(4):411-417. Published online August 31, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.4.411

4,035 View
90 Download
12 Crossref

Abstract PDF PubReader

Background

To evaluate the clinical efficacy of sitagliptin for reducing plasma glucose levels in Korean subjects with type 2 diabetes mellitus during a 14-week treatment period.

Methods

Our study design involved the addition of 100 mg sitagliptin once-daily to three ongoing combination therapy regimens and changing from glimepiride and metformin to sitagliptin and metformin.

Results

The addition of sitagliptin 100 mg/day produced a statistically significant reduction in mean HbA1c level (mean HbA1c reduction of 0.99±0.85%, P<0.01). In the group taking a combination of sitagliptin and metformin (n=143, initial mean HbA1c level=7.48%), the reductions in HbA1c, 2-hour postprandial glucose, and fasting glucose levels were 0.72±0.76% (P<0.01), 47±65 mg/dL (P<0.01), and 15±44 mg/dL (P<0.01), respectively. In the group taking a combination of sitagliptin, glimepiride, and metformin (n=125, initial mean HbA1c level=8.42%), the reductions in HbA1c, 2-hour postprandial glucose, and fasting glucose levels were 1.09±0.86% (P<0.01), 62±64 mg/dL (P<0.01), and 31±45 mg/dL (P<0.01), respectively. In the group taking a combination of sitagliptin, glimepiride, metformin, and α-glucosidase inhibitor (n=63, initial mean HbA1c level=9.19%), the reductions in HbA1c, 2-hour postprandial glucose, and fasting glucose levels were 1.27±0.70% (P<0.01), 72±65 mg/dL (P<0.01), and 35±51 mg/dL (P<0.01), respectively. In the group that had previous hypoglycemic events and that changed from glimepiride to sitagliptin, HbA1c level did not change but fasting glucose increased significantly (14±29 mg/dL, P<0.01).

Conclusion

Sitagliptin combination therapy for 14 weeks significantly improved glycemic control and was well-tolerated in Korean subjects with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by

Impact of Treviamet® & Treviamet XR® on quality of life besides glycemic control in type 2 DM patients
Asima Khan, Muhammad Adnan Kanpurwala, Riasat Ali Khan, Najum F. Mahmudi, Verumal Lohano, Shakeel Ahmed, Majid Khan, Fareed Uddin, Syed Mohammad Ali, Maliha Saghir, Syed Hussain Baqar Abidi, Jahanzeb Kamal
BMC Endocrine Disorders.2023;[Epub] CrossRef
Efficacy and safety of sitagliptin/metformin fixed‐dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double‐blind study
Sang Soo Kim, In Joo Kim, Kwang Jae Lee, Jeong Hyun Park, Young Il Kim, Young Sil Lee, Sung Chang Chung, Sang Jin Lee
Journal of Diabetes.2017; 9(4): 412. CrossRef
Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
Hyun Min Kim, Jung Soo Lim, Byung-Wan Lee, Eun-Seok Kang, Hyun Chul Lee, Bong-Soo Cha
Endocrinology and Metabolism.2015; 30(1): 84. CrossRef
Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta‐analysis
JM. Amate, T. Lopez‐Cuadrado, N. Almendro, C. Bouza, Z. Saz‐Parkinson, R. Rivas‐Ruiz, J. Gonzalez‐Canudas
International Journal of Clinical Practice.2015; 69(3): 292. CrossRef
Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
Ye An Kim, Won Sang Yoo, Eun Shil Hong, Eu Jeong Ku, Kyeong Seon Park, Soo Lim, Young Min Cho, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi
Diabetes & Metabolism Journal.2015; 39(6): 489. CrossRef
Sitagliptin for Elderly Patients Aged 75 Years or Older with Inadequately Controlled Type 2 Diabetes with Common Antidiabetes Treatments
Katsunori Suzuki, Yurie Mistuma, Takaaki Sato, Mariko Hatta
International Journal of Clinical Medicine.2015; 06(09): 672. CrossRef
Short‐ and long‐term effect of sitagliptin after near normalization of glycemic control with insulin in poorly controlled Japanese type 2 diabetic patients
Keiko Fujisawa, Tetsuyuki Yasuda, Hideaki Kaneto, Naoto Katakami, Mayumi Tsuji, Fumiyo Kubo, Shugo Sasaki, Kazuyuki Miyashita, Toyoko Naka, Ryuuichi Kasami, Akio Kuroda, Munehide Matsuhisa, Iichiro Shimomura
Journal of Diabetes Investigation.2014; 5(5): 548. CrossRef
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
Chun-Jun Li, Xiao-Juan Liu, Lian Bai, Qian Yu, Qiu-Mei Zhang, Pei Yu, De-Min Yu
Diabetology & Metabolic Syndrome.2014;[Epub] CrossRef
Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes
Sun Ok Song, Kwang Joon Kim, Byung‐Wan Lee, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee
Journal of Diabetes Investigation.2014; 5(5): 554. CrossRef
Efficacy of vildagliptin on glucose fluctuation in Japanese type 2 diabetic patients with ongoing sulfonylurea based oral glycemic agent therapy
Keiji Yoshioka, Haruhiko Isotani, Shin-ichiro Ohashi, Minoru Imamura
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2013; 7(1): 32. CrossRef
Glimepiride Strongly Enhances the Glucose-Lowering Effect in Triple Oral Antidiabetes Therapy with Sitagliptin and Metformin for Japanese Patients with Type 2 Diabetes Mellitus
Keiko Arai, Hajime Maeda, Sin-ichiro Sirabe, Ritsuko Yamamoto, Mikio Yamauchi, Tetsuyuki Hirao, Setsuko Hirao, Koichi Hirao
Diabetes Technology & Therapeutics.2013; 15(4): 335. CrossRef
Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy
Mitsuyoshi Takahara, Toshihiko Shiraiwa, Hideaki Kaneto, Naoto Katakami, Taka-aki Matsuoka, Iichiro Shimomura
Endocrine Journal.2012; 59(12): 1131. CrossRef

Relationship Between Metabolic Syndrome and Risk of Chronic Complications in Koreans with Type 2 Diabetes.: Hye Soo Chung, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Doo Man Kim, Choon Hee Chung, Dong seop Choi; Korean Diabetes J. 2009;33(5):392-400. Published online October 1, 2009; DOI: https://doi.org/10.4093/kdj.2009.33.5.392

2,320 View
30 Download
6 Crossref

Abstract PDF

BACKGROUND
We examined the relationships between components of metabolic syndrome at the time of diagnosis of type 2 diabetes, and the development of chronic complications in Korean patients with type 2 diabetes. METHODS: The medical records of patients with type 2 diabetes who had undergone treatment for at least five years prior were collected from 10 general hospitals in Korea. Among a total of 1,418 patients reviewed for possible inclusion in this study, 603 patients were selected, and the occurrence of complications among these patients was evaluated. RESULTS: Among the 603 patients (male, 253; female, 350), 154 males (60.8%) and 266 females (76.0%) were diagnosed with metabolic syndrome at the time of initial diagnosis of type 2 diabetes. The incidence of chronic complications (average follow-up 15.2 +/- 4.9 years) included 60 cases of coronary artery disease (CAD), 57 cases of cerebrovascular accident (CVA), 268 cases of diabetic retinopathy (DR), 254 cases of diabetic nephropathy (DN), and 238 cases of diabetic peripheral neuropathy (DPN). As compared to patients without metabolic syndrome, the adjusted relative risks (95% CI) of incidental diabetic complications in patients with metabolic syndrome were 3.28 (1.40~7.71) for CAD, 2.04 (0.86~4.82) for CVA, 1.53 (1.10~2.14) for DR, 1.90 (1.29~2.80) for DN, and 1.51, (1.06~2.14) for DPN. With the addition of just one constituent of metabolic syndrome, the relative risk of developing CAD, CVD, DR, DN, and DPN increased by 2.08 (95% CI, 1.27~3.40), 1.16 (0.80~1.66), 1.09 (0.93~1.26), 1.29 (1.06~1.57) and 1.06 (0.87~1.26), respectively. CONCLUSION: Metabolic syndrome in Korean patients with type 2 diabetes increases the risk of developing both macrovascular and microvascular complications.

Citations

Citations to this article as recorded by

COVID-19 pandemic: Effects of national lockdown on the state of health of patients with type 2 diabetes mellitus in a Moroccan population
Hamid Farhane, Majida Motrane, Fatima-Ezzahra Anaibar, Aïcha Motrane, Said Nassor Abeid, Nourdin Harich
Primary Care Diabetes.2021; 15(5): 772. CrossRef
Profil clinique du syndrome métabolique et facteurs associés à sa présence au cours du diabète de type 2 à Ouagadougou (Burkina Faso)
O. Guira, H. Tiéno, Y. Sagna, P. Mayodé, D. Yanogo, L. Zoungrana, C.-G. Kyélem, M.-T. Yaméogo, J.-Y. Drabo
Médecine des Maladies Métaboliques.2016; 10(1): 70. CrossRef
The Relationship between Metabolic Syndrome and Quality of Life in Korean Adult Women
Hyung-Su Park, Jong Park
The Journal of the Korea institute of electronic communication sciences.2013; 8(4): 639. CrossRef
Diabetes Risk Analysis Model with Personalized Food Intake Preference
So-Hye Jeon, Nam-Hyun Kim
Journal of the Korea Academia-Industrial cooperation Society.2013; 14(11): 5771. CrossRef
Comorbidity Study on Type 2 Diabetes Mellitus Using Data Mining
Hye Soon Kim, A Mi Shin, Mi Kyung Kim, Yoon Nyun Kim
The Korean Journal of Internal Medicine.2012; 27(2): 197. CrossRef
Cardio-Metabolic Features of Type 2 Diabetes Subjects Discordant in the Diagnosis of Metabolic Syndrome
Sa Rah Lee, Ying Han, Ja Won Kim, Ja Young Park, Ji Min Kim, Sunghwan Suh, Mi-Kyoung Park, Hye-Jeong Lee, Duk Kyu Kim
Diabetes & Metabolism Journal.2012; 36(5): 357. CrossRef

First
Prev
Page of 1
Next
Last

Search